Johnson & Johnson (NYSE:JNJ) Posts Earnings Results

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Wednesday. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06, FiscalAI reports. The firm had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.02 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business’s revenue was up 6.6% on a year-over-year basis. During the same period last year, the company earned $2.77 earnings per share. Johnson & Johnson updated its FY 2026 guidance to 11.600-11.750 EPS.

Here are the key takeaways from Johnson & Johnson’s conference call:

• Johnson & Johnson beat Q2 expectations and raised full-year guidance. Worldwide sales were $25.3 billion, operational growth was 5.6% despite a STELARA headwind, and management lifted 2026 operational sales growth and EPS targets.
• Innovative Medicine remained the main growth engine. Segment sales rose 6.8%, driven by strong oncology, immunology, and neuroscience performance, with standout growth from DARZALEX, TREMFYA, CAPLYTA, and new launches like ICOTYDE and INLEXZO.
• Several pipeline and launch programs are showing early momentum. Management said ICOTYDE has passed 10,000 patients, INLEXZO is reaching about one-third of eligible patients in the U.S., and new data at ASCO and elsewhere support longer-term growth in oncology and immunology.
• MedTech growth was solid overall, but cardiovascular was softer than expected. Q2 MedTech sales rose 3.6%, while electrophysiology faced China inventory headwinds and Abiomed was pressured by more cautious physician behavior after recent clinical data.
• Management expects second-half acceleration and highlighted multiple catalysts. The company cited upcoming FDA decisions and data readouts for products including IMAAVY, OTTAVA, VARIPULSE Pro, milvexian, and additional oncology programs, while also reiterating a path to double-digit growth by the end of the decade.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $247.55 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $595.90 billion, a price-to-earnings ratio of 28.62, a PEG ratio of 2.42 and a beta of 0.24. The stock has a 50 day moving average of $238.64 and a 200 day moving average of $234.20. Johnson & Johnson has a 12 month low of $159.80 and a 12 month high of $269.43.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson beat Q2 estimates on both earnings and revenue, driven by strong pharmaceutical sales and growth in key drugs like Darzalex and Tremfya.
• Positive Sentiment: The company raised its full-year 2026 outlook, signaling management confidence in continued momentum across the business.
• Positive Sentiment: J&J announced a quarterly dividend of $1.34 per share, reinforcing its appeal as a defensive income stock.
• Neutral Sentiment: Analysts now rate JNJ an average of “Moderate Buy,” suggesting sentiment is constructive but not uniformly bullish. Johnson & Johnson (NYSE:JNJ) Receives Average Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: Investors are still weighing strong innovation and pipeline progress against uneven MedTech results and broader uncertainty around the company’s risk profile.
• Negative Sentiment: The stock fell after earnings because the results were viewed as solid but not exceptional, and the market had already priced in a strong report.
• Negative Sentiment: Ongoing talc litigation remains a key overhang that continues to cap enthusiasm for the shares.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds have recently made changes to their positions in JNJ. T. Rowe Price Investment Management Inc. grew its position in Johnson & Johnson by 84.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,900 shares of the company’s stock valued at $2,877,000 after buying an additional 6,364 shares during the period. Strive Financial Group LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $199,000. Blue Sparrow LLC DE bought a new stake in Johnson & Johnson in the fourth quarter worth about $37,106,000. Mercer Global Advisors Inc. ADV boosted its stake in Johnson & Johnson by 10.8% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 849,734 shares of the company’s stock valued at $167,341,000 after acquiring an additional 82,929 shares during the last quarter. Finally, Summit Global Investments grew its position in shares of Johnson & Johnson by 3.8% during the 4th quarter. Summit Global Investments now owns 12,857 shares of the company’s stock valued at $2,661,000 after acquiring an additional 465 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on JNJ shares. TD Cowen raised their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday. Weiss Ratings lowered Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, June 15th. The Goldman Sachs Group increased their price objective on Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Barclays raised their target price on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. Finally, Raymond James Financial upped their price target on Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $261.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.